This BCC Research report explores the present and future strategies within the manufacturing of the protein drugs market, which includes peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. Forecast provided from 2015 through 2020.
Use this report to:
Explore present and future strategies within manufacturing of the protein drugs market. Analyze the protein drug market and its applications, regulatory environment, technology, market projections and market shares. Gain information about the history of therapeutic proteins and its manufacturing technologies. Relevant patent analysis and profiles of companies that lead manufacturing in the protein drug industry
The global protein drugs market reached nearly $174.7 billion in 2015 and should reach nearly $248.7 billion by 2020 increasing at a compound annual growth rate (CAGR) of 7.3% through 2020. The U.S., leader in the protein drugs market, reached nearly $92.0 billion in 2015 and should reach $154.1 billion by 2020 at a CAGR of 10.9% through 2020. Europe as a segment reached $42.2 billion in 2015 and should reach $48.1 billion by 2020, at a CAGR of 2.6% through 2020.
Proteins play the most diverse role in the body. Protein drug products have many advantages over small-molecule drugs; their actions are highly specific and they are less likely to interfere with normal biological processes, and are often well tolerated by the body. The protein drug market is highly segmented and promising. Protein drugs can be manufactured through many different ways. They are either created through recombinant deoxyribonucleic acid (rDNA) technology, or can be isolated as naturally occurring substances from animals, microorganisms and insects. BCC Research’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for manufacturing of protein drugs.
This report explores the present and future strategies within the manufacturing of the protein drugs market, which includes peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. The history of the market, the restraining factors and the needs of the market are discussed in this report. The classification of these products and their manufacturing processes are also detailed in this report.
An analysis of the industry structure of protein drug products has been conducted.
Revenues are broken down by region. Sales figures are estimated for the five-year period from 2015 through 2020. The market by manufacturing process for these protein drugs is discussed separately in the report. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THIS STUDY
Protein drugs play an important role in the biopharmaceutical industry. The increase in incidences of chronic diseases such as cancer, various hormone and enzymatic disorders, asthma and autoimmune diseases have added to the growth of the protein drug market. Outstanding improvements in technologies such as mass spectrometry, advances in molecular genetics, and progress in production technologies are driving the market’s growth. Extensive research in the manufacturing process of protein drugs has revealed their usage in developing efficient, user-friendly and affordable products.
Modern industries have now begun to explore the advantages of these technologies for manufacturing protein drugs in their productions and processes.
R&D spending, along with increasing competition, patent expiries and new technologies are giving a new direction to the market. The advancements, new product launches and the changing lifestyle have influenced the market to grow in the future.
This study looks at almost all the systems affected by these factors. Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type in light of the new technologies, growing competition, and changing customer needs.
SCOPE OF THE STUDY
The scope of this study covers manufacturing of protein drugs technologies. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. This report covers the currently used six techniques in manufacturing of protein therapeutics, which includes fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. The protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes and blood factors. The market is also analyzed on the basis of the manufacturing process used in making therapeutic protein drugs.
Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the manufacturing of the protein drug industry. Some of the major players of the market include Eli Lilly & Co., Abbvie Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Novo Nordisk AG, Novartis AG, Merck & Co., Merck KGaA and Amgen Inc..
Our reports have been used by over 10K customers, including:
Cachexia Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Cachexia Global Clinical Trials Review, H2, 2018" provides an overview of Cachexia clinical trials scenario.This report provides top line data relating to the clinical trials on Cachexia. Report includes...
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry Summary Rheumatic disorders are a wide range of conditions which are characterized by chronic pain, with some of the most common conditions being...
House Dust Mite Allergy - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2019, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape. House dust...
Birch Pollen Allergy Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Birch Pollen Allergy Global Clinical Trials Review, H2, 2018" provides an overview of Birch Pollen Allergy clinical trials scenario.This report provides top line data relating to the clinical...
Renal Diseases Drug Development Pipeline Review, 2018 Summary Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The...
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2018 Summary Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.